1.Baune BT, Hohoff C, Berger K, et al. Association of the COMT val158met Variant with Antidepressant Treatment Response in Major Depression. Neuropsychopharmacology (2008) 33, 924–932.

2. Zeier Z, Carpenter L, Kalin N, et al. Clinical Implementation of Pharmacogenetic Decision Support Tools for Antidepressant Drug Prescribing. Am J Psychiatry. 2018 September 01; 175(9): 873–886.

3. PharmGKB Web site. http://Clinical Guideline Annotations (pharmgkb.org). Accessed November 2nd, 2022.

4. Wakeno M, Kato M, Okugawa G, et al. The Alpha 2A-Adrenergic Receptor Gene Polymorphism Modifies Antidepressant Responses to Milnacipran. Journal of Clinical Psychopharmacology. October 2008 – Volume 28 – Issue 5 – p 518-524.

5. Polanczyk G, Zeni C, Genro J, et al. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention- deficit/hyperactivity disorder. Arch Gen Psychiatry. 2007 Feb;64(2):218-24.

6. Alenius M, Wadelius M, Dahl ML, et al. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. Journal of Psychiatric Research. Volume 42, Issue 11, September 2008, Pages 884-893.

7. Merve DO, Zuchal U, Nazan YA, et al. The relationship between the serotonin 2A receptor gene –1438A/G and 102T/C polymorphisms and citalopram/sertraline-induced nausea in major depressed patients. Human Psychopharmacology. Volume 33, Issue5, September 2018.

8. Paes LA, Torre OH, Henriques TB, et al. Association between serotonin 2C receptor gene (HTR2C) polymorphisms and psychopathological symptoms in children and adolescents. Braz J Med Biol Res. 2018; 51(8): e7252.

9. Sun Q, Yuan F, Yuan R, et al. GRIK4 and GRM7 gene may be potential indicator of venlafaxine treatment responses in Chinese of Han ethnicity. Medicine. 2019 May; 98(19): e15456.

10. Milanesi E, Bonvicini C, Congiu C, et al. The role of GRIK4 gene in treatment-resistant depression. Cambridge University Press: 03 July 2015.

11. Zhu J, Klein-Fedyshin M, Stevenson JM. Serotonin Transporter Gene Polymorphisms and Selective Serotonin Reuptake Inhibitor Tolerability: Review of Pharmacogenetic Evidence. Pharmacotherapy, 27 June 2017.

12. Murphy GM, Kremer C, Rodrigues HE, et al. Pharmacogenetics of Antidepressant Medication Intolerance. Am J Psychiatry. 2003; 160:1830–1835.

13. Brasch-Anderson, Moller MU, Christiansen, et al. A candidate gene study of serotonergic pathway genes and pain relief during treatment with escitalopram in patients with neuropathic pain shows significant association to serotonin receptor2C (HTR2C). European Journal of Clinical Pharmacology. Volume 67, Article number: 1131 (2011)

14. Wan L, Li Y, Zhangun Z, et al. Methylenetetrahydrofolate reductase and psychiatric diseases. Translational Psychiatry. (2018) 8:242.

15. Peerbooms OLJ, Van Os J, Drukker N, et al. Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: Evidence for a common genetic vulnerability? Brain, Behavior, and Immunity, Volume 25, Issue 8, November 2011, Pages 1530-1543.

16. De Gregori M, Diatchenko L, Belfer I, et al. OPRM1 receptor as new biomarker to help the prediction of post mastectomy pain and recurrence in breast cancer. Minerva Anestesiol. 2015 Aug;81(8):894-900.

17. Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003 ;28(8):1546–52.

18. Hwang IC, Park Ji-Young, Myung SK, et al. OPRM1 A118G Gene Variant and Postoperative Opioid Requirement: A Systematic Review and Meta-analysis. Anesthesiology. 2014; 121:825-34.

19. Chatti I, Woillard JB, Mili A, et al. Genetic Analysis of Mu and Kappa Opioid Receptor and COMT Enzyme in Cancer Pain Tunisian Patients Under Opioid Treatment. Iran J Public Health. 2017Dec;46(12): 1704–1711.

20. Reyes-Gibby C, Shete S, Rakvag T, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain. 2007 Jul;130(1-2):25-30.

21. Agarwal D, Udoji MA, Trescot A. Genetic Testing for Opioid Pain Management: A Primer. Pain Ther. (2017) 6:93-105.

22. Perez de los Cobos J, Baiget M, Trujols J, et al. Allelic and genotypic associations of DRD2 Taq I A polymorphism with heroin dependence in Spanish subjects: a case control study. Behavioral and Brain Functions. Volume 3, Article number: 25 (1 June 2007).

23. Vereczkei A, Demetrovics Z, Szekely, et al. Multivariate Analysis of Dopaminergic Gene Variants as Risk Factors of Heroin Dependence. Plos One. Published: June 28, 2013.

24. McD young R, Lawford BR, Nutting A, et al. Advances in molecular genetics and the prevention and treatment of substance misuse: Implications of association studies of the A1 allele of the D2 dopamine receptor gene. Addictive Behaviors. Volume 29, Issue 7, September 2004, Pages 1275-1294.

25. Ramaekers JG, Van Wel JH, Spronk D, et al. Cannabis and cocaine decrease cognitive impulse control and functional corticostriatal connectivity in drug users with low activity DBH genotypes. Brain Imaging and Behavior. (2016) 10:1254–1265.

26. Okahisa Y, Ujike H, Takai M, et al. Association Study of Dopamine β-Hydroxylase Gene with Methamphetamine Psychosis. Journal of Drug and Alcohol Research. Vol. 3 (2014).

27. Patriquin MA, Bauer IE, Soares JC, et al. Addiction pharmacogenetics: A systematic review of the genetic variation of the dopaminergic system. Psychiatr Genet. 2015 October; 25(5): 181–193.

28. Ujike H, Nomura A, Morita Y, et al. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J Clin Psychiatry. 2008 Sep;69(9):1416.

29. Wilkie MJV, Smith G, Day Rk, et al. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. The Pharmacogenomics Journal.(2009) 9, 61–70.

30. Drago A, De Ronchi A, Serretti A. Pharmacogenetics of antidepressant response: An update . Human genomics. VOL 3. NO 3. 257 –274 April 2009

31. McMahon FJ, Buervenich S, Charney D, et al. Variation in the Gene Encoding the Serotonin 2A Receptor Is Associated with Outcome of Antidepressant Treatment. Am J. Hum. Genet. 2006; 78:804–814.

32. www.snpedia.com/index.php/ABCB1. Accessed March 21st, 2023.

33. www.ncbi.nlm.nih.gov/snp/rs1045642. Accessed March 21st, 2023.

34. CPIC: https://cpicpgx.org/guidelines/cpic-guideline-for-statins. Accessed March 21st, 2023.

35. www.snpedia.com/index.php/APOE. Accessed March21st, 2023.

36. Ariza MJ, Sánchez-Chaparro MA, Barón FJ, et al. Research article Additive effects of LPL, APOA5 and APOE variant combinations on triglyceride levels and hypertriglyceridemia: results of the ICARIA genetic sub-study BMC Medical Genetics 2010, 11:66.

37. https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/). Accessed November 22nd, 2022.

38. https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/). Accessed November 22nd, 2022.

39. https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/). Accessed November 22nd, 2022.

40. https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/ Accessed November 22nd, 2022.

41 .https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/ Accessed November 22nd, 2022.

42. https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/ Accessed November 22nd, 2022.

43. https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/ Accessed November 22nd, 2022.

44. https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/) Accessed November 22nd, 2022.

45. https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/ Accessed November 22nd, 2022.

46.https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/ Accessed November 22nd, 2022.

47.https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/ Accessed November 22nd, 2022.

48. https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/) Accessed November 22nd, 2022.

49. Ramaekers JG, Van Wel JH, Spronk D, et al. Cannabis and cocaine decrease cognitive impulse control and functional corticostriatal connectivity in drug users with low activity DBH genotypes. Brain Imaging and Behavior. (2016) 10:1254–1265.

50. Okahisa Y, Ujike H, Takai M, et al. Association Study of Dopamine β-Hydroxylase Gene with Methamphetamine Psychosis. Journal of Drug and Alcohol Research. Vol. 3 (2014).

51. Patriquin MA, Bauer IE, Soares JC, et al. Addiction pharmacogenetics: A systematic review of the genetic variation of the dopaminergic system. Psychiatr Genet. 2015 October; 25(5): 181–193.

52. Legnani C, G Palareti G, , G Guazzaloca G, et al. Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use. Eur Heart J.2002 Jun;23(12):984-90.

53. McDaid A , Logette E, Buchillier V, et al. Risk prediction of developing venous thrombosis in combined oral contraceptive users. PLOS ONE. July 27, 2017.

54.Ida Martinelli I, Battaglioli, I , Ilaria Burgo I, et al. Oral contraceptive use, thrombophilia and their interaction in young women with ischemic stroke. Haematologica. 2006 Jun;91(6):844-7.

55. Cayla G, Hulot JS, O’Connor SA, et al. Angiographic, and Genetic Factors Associated With Early Coronary Stent Thrombosis. JAMA. 2011;306(16):1765-1774.

56. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagulation & Fibrinolysis 15(1):p 89-93, January 2004.

57. https://cpicpgx.org/guidelines/guideline-for-atazanavir-and-ugt1a1/Accessed November 22nd, 2022.

58. Lankisch TO,  Moebius U,  Wehmeier M, et al. Gilbert’s disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology. 2006 Nov;44(5):1324-32.

59. Riera P, Salazar J,  Anna C. Virgili AC, et al. Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan‐induced severe toxicity. Br J Clin Pharmacol. 2018 Jun; 84(6): 1389–1392. Published online 2018 Apr 16. doi: 10.1111/bcp.13574.

60. www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations. Accessed March 23rd, 2023.

61. UGT1A1 UDP glucuronosyltransferase family 1 member A1 [Homo sapiens (human)] – Gene – NCBI (nih.gov) Accessed March 23rd, 2023.

62. He X, Hesse LM, Hazarika S, et al. Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. Br J Clin Pharmacol. 2009 Nov;68(5):721-30.

63. Chung JY,   Cho JY,  Yu KS, et al. Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther. 2005 Jun;77(6):486-94.

64. SLC6A4 solute carrier family 6 member 4 [Homo sapiens (human)] – Gene – NCBI (nih.gov) Accessed March 23rd, 2023.

65. The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin‐associated musculoskeletal symptoms (cpicpgx.org). Accessed March 23rd, 2023.

66. MTHFR methylenetetrahydrofolate reductase [Homo sapiens (human)] – Gene – NCBI (nih.gov) Accessed March 23rd, 2023.

67. ITGB3 gene: MedlinePlus Genetics. Accessed March 23rd, 2023.

68. Morita H,  Taguchi J,  Kurihara H, Genetic Polymorphism of 5,10-Methylenetetrahydrofolate Reductase (MTHFR) as a Risk Factor for Coronary Artery Disease. Circulation. Volume 95, Issue 8, 15 April 1997; Pages 2032-2036.